Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND-2: Ceritinib in ALK+ NSCLC previously treated with chemotherapy and crizotinib
NCT01685060Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2012
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of ceritinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Nov 2012; status: completed.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01685060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01685060.